4-PrO-DMT
1Provenance card
the boundary, as counts
Sources
2926 with DOI
6 strong · 19 moderate · 4 weak
Compilations
12026-09-05T01:39:43.441Z
pipeline-v5 · prompt aa4a2f8ca809
Decisions
29last ruled 2026-09-17
1 awaiting a ruling
Issued documents
32026-09-17T22:23:25.104Z
notice · info card · emergency
Searches
203 with no results
queries and counts on the build
Claims checked
8855 supported
55 supported · 33 not
Correspondence
0received
consent field ships in Phase 4
Edges
331
derivations recorded for this entity
Complete over 29 sources, 1 compilation, and 29 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/4-pro-dmt/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-09-17issueIssued emergency
- 2026-09-17issueIssued info_card
- 2026-09-17issueIssued notice
- 2026-09-17publicationPublication — publishDev Bypass
- 2026-09-07srcChemistry and Structure-Activity Relationships of Psychedelics.
- 2026-09-07srcSerotonin toxicity of serotonergic psychedelics
- 2026-09-07srcCardiovascular safety of psychedelic medicine: current status and future directions
- 2026-09-07srcTryptamines (Chapter 18 in Novel Psychoactive Substances, 2nd edition)
- 2026-09-07srcSerotonin 5-HT2A, 5-HT2C and 5-HT1A receptor involvement in the acute effects of psilocybin in mice
- 2026-09-07srcThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
- 2026-09-07src5-HT2A receptors: Pharmacology and functional selectivity
- 2026-09-07srcSerotonergic hallucinogens and emerging targets for addiction pharmacotherapies
- 2026-09-07srcNovel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders
- 2026-09-07srcPsychedelic-like Activity of Norpsilocin Analogues
- 2026-09-07srcSynthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines
- 2026-09-07srcReceptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
- 2026-09-07srcPsychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
- 2026-09-07srcIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
- 2026-09-07srcNeuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD): A comparative analysis with psychedelic-using and non-using controls
- 2026-09-07srcClassic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures
- 2026-09-07srcHypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine
- 2026-09-07srcDevelopment and validation of an analytical method for the determination of select 4-position ring-substituted tryptamines in plasma by LC-MS/MS
- 2026-09-07srcPharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms
- 2026-09-07srcPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
- 2026-09-07srcStructure-based discovery of nonhallucinogenic psychedelic analogs
- 2026-09-07srcRecreational use, analysis and toxicity of tryptamines.
- 2026-09-07srcIn vitro and in vivo metabolism of psilocybin's active metabolite psilocin
- 2026-09-07srcTherapeutic use of psilocybin: Practical considerations for dosing and administration
- 2026-09-07srcPharmacokinetics of Psilocybin: A Systematic Review
- 2026-09-07srcResearch on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice
- 2026-09-07src4-PrO-DMT
- 2026-09-07src4-PrO-DMT
- 2026-09-07src4-propanoyloxy DMT product page
- 2026-09-05proposal2 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-09-05proposalcontraindication · other
- 2026-09-05proposalcontraindication · other
- 2026-09-05proposalcontraindication · psychiatric
- 2026-09-05proposalcontraindication · cardiovascular
- 2026-09-05proposalcontraindication · pregnancy_breastfeeding
- 2026-09-05proposalcontraindication · other
- 2026-09-05proposalcontraindication · neurological
- 2026-09-05proposalcontraindication · psychiatric
- 2026-09-05proposalduration · oral · total
- 2026-09-05proposalduration · oral · onset
- 2026-09-05proposaldosage · oral
- 2026-09-05proposaltolerance
- 2026-09-05proposaltoxicity
- 2026-09-05proposaltimeline · oral · afterglow
- 2026-09-05proposaltimeline · oral · resolution
- 2026-09-05proposaltimeline · oral · peak
- 2026-09-05proposaltimeline · oral · come_up
- 2026-09-05proposaltimeline · oral · onset
- 2026-09-05proposaldose_tier · heavy
- 2026-09-05proposaldose_tier · strong
- 2026-09-05proposaldose_tier · common
- 2026-09-05proposaldose_tier · light
- 2026-09-05proposaldose_tier · threshold
- 2026-09-05revisionRevision 2
- 2026-09-05absenceSearched ClinicalTrials.gov for "psilocin prodrug 4-propionyloxy tryptamine psychedelic" — no results
- 2026-09-05absenceSearched ClinicalTrials.gov for "4-PrO-DMT psilocin analog" — no results
- 2026-09-05absenceSearched PubMed for "psilocin ester analogs pharmacology serotonin receptor" — no results
- 2026-09-05genGeneration — pipeline-v5 · with 5 morepipeline-v5
- 2026-09-05rungeneration run
- 2026-09-05importImported from Curiosity v1
- 2026-09-05revisionRevision 1
The same entries, as forms: six forms.